{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:41:59Z","timestamp":1767339719254,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.msard.2021.102842","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T04:03:22Z","timestamp":1613016202000},"page":"102842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance"],"prefix":"10.1016","volume":"50","author":[{"given":"Stina","family":"K\u00e5gstr\u00f6m","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"F\u00e4lt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Berglund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrik","family":"Piehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Lycke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6364","key":"10.1016\/j.msard.2021.102842_bib0001","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.msard.2021.102842_bib0002","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","article-title":"Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring","volume":"10","author":"Kappos","year":"2011","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.msard.2021.102842_bib0003","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1016\/j.msard.2021.102842_bib0004","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.msard.2021.102842_bib0005","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.neurol.2019.01.270","article-title":"Incidence of natalizumab-associated progressive multifocal leucoencephalopathy and its relationship with the pattern of natalizumab exposure over time","volume":"175","author":"Giovannoni","year":"2019","journal-title":"Revue Neurologique"},{"issue":"1","key":"10.1016\/j.msard.2021.102842_bib0006","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamaneurol.2019.2670","article-title":"Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France","volume":"77","author":"Vukusic","year":"2020","journal-title":"JAMA Neurology"},{"issue":"8","key":"10.1016\/j.msard.2021.102842_bib0007","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1177\/1352458511403794","article-title":"High nationwide prevalence of multiple sclerosis in Sweden","volume":"17","author":"Ahlgren","year":"2011","journal-title":"Mult Scler"},{"issue":"9","key":"10.1016\/j.msard.2021.102842_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108599","article-title":"High nationwide incidence of multiple sclerosis in Sweden","volume":"9","author":"Ahlgren","year":"2014","journal-title":"PLoS One"},{"issue":"199","key":"10.1016\/j.msard.2021.102842_bib0009","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/ane.12425","article-title":"The Swedish MS registry - clinical support tool and scientific resource","volume":"132","author":"Hillert","year":"2015","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"10.1016\/j.msard.2021.102842_bib0010","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1177\/1352458510394701","article-title":"A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis","volume":"17","author":"Holmen","year":"2011","journal-title":"Mult Scler"},{"issue":"Suppl 3","key":"10.1016\/j.msard.2021.102842_bib0011","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10072-010-0345-y","article-title":"Swedish natalizumab (Tysabri) multiple sclerosis surveillance study","volume":"31","author":"Piehl","year":"2011","journal-title":"Neurol Sci"},{"issue":"11","key":"10.1016\/j.msard.2021.102842_bib0012","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458513477925","article-title":"Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort","volume":"19","author":"Olsson","year":"2013","journal-title":"Mult Scler"},{"issue":"11","key":"10.1016\/j.msard.2021.102842_bib0013","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa0810316","article-title":"Progressive multifocal leukoencephalopathy after natalizumab monotherapy","volume":"361","author":"Linda","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2021.102842_bib0014","unstructured":"Socialstyrelsen. Nationella riktlinjer 2016 V\u00e5rd vid multipel skleros och Parkinsons sjukdom \u2013 St\u00f6d f\u00f6r styrning och ledning. www.socialstyrelsen.se; 2016."},{"issue":"15","key":"10.1016\/j.msard.2021.102842_bib0015","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102842_bib0016","unstructured":"Biogen. Global Natalizumab (TYSABRI) Postmarketing PML Update. Update December 2018 2018."},{"issue":"1","key":"10.1016\/j.msard.2021.102842_bib0017","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ana.23893","article-title":"JC virus antibody status underestimates infection rates","volume":"74","author":"Berger","year":"2013","journal-title":"Ann Neurol"},{"issue":"23","key":"10.1016\/j.msard.2021.102842_bib0018","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMc1214233","article-title":"JC viremia in natalizumab-treated patients with multiple sclerosis","volume":"368","author":"Major","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.msard.2021.102842_bib0019","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J Clin Virol"},{"issue":"4","key":"10.1016\/j.msard.2021.102842_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004084","article-title":"JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants","volume":"10","author":"Sundqvist","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.msard.2021.102842_bib0021","unstructured":"Svenska Neuroregister. \u00c5rsrapport 2018-2019 Yearly report. www.neuroreg.se; 2019."},{"issue":"6","key":"10.1016\/j.msard.2021.102842_bib0022","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00415-014-7325-8","article-title":"Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients","volume":"261","author":"Sorensen","year":"2014","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.msard.2021.102842_bib0023","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1001\/jamaneurol.2013.6240","article-title":"Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study","volume":"71","author":"Cohen","year":"2014","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.msard.2021.102842_bib0024","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.msard.2021.102842_bib0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/ane.12963","article-title":"Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?","volume":"138","author":"Berntsson","year":"2018","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"10.1016\/j.msard.2021.102842_bib0026","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1212\/WNL.0000000000004926","article-title":"The national incidence of PML in Sweden, 1988-2013","volume":"90","author":"Iacobaeus","year":"2018","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821001085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821001085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:53:59Z","timestamp":1761900839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821001085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":26,"alternative-id":["S2211034821001085"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102842","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102842","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102842"}}